XML 56 R40.htm IDEA: XBRL DOCUMENT v2.4.0.8
Summary of Significant Accounting Policies (Textual) (Details) (USD $)
3 Months Ended 12 Months Ended
Dec. 31, 2013
Sep. 30, 2013
Jun. 30, 2013
Mar. 31, 2013
Dec. 31, 2012
Sep. 30, 2012
Jun. 30, 2012
Mar. 31, 2012
operating_segment
Dec. 31, 2013
Dec. 31, 2012
Dec. 31, 2011
Dec. 31, 2010
Accounting Policies [Line Items]                        
Additional Cash and Cash Equivalent Related Text                 3 months      
Assets Held-for-sale, Current $ 2,179,000       $ 0       $ 2,179,000 $ 0    
Investment Maturity Date                 1 year      
Other than Temporary Impairment Losses, Investments                   753,000    
Entity-Wide Revenue, Major Customer, Percentage                 10.00%      
Number of Operating Segments               1 1      
Net income (loss) 9,813,000 9,262,000 12,605,000 9,623,000 15,538,000 2,309,000 5,519,000 7,490,000 41,303,000 30,857,000 16,550,000  
Net cash provided by (used in) operating activities                 22,998,000 11,892,000 490,000  
Accumulated deficit 256,859,000       215,556,000       256,859,000 215,556,000    
Cash and cash equivalents 22,130,000       32,003,000       22,130,000 32,003,000 25,762,000 72,396,000
Cash, Cash Equivalents and Marketable Securities [Abstract]                        
Recorded impairment in condensed consolidated statement of operations as sales, general and administrative expenses                 0      
Decrease (increase) in restricted cash                 800,000 0 (45,000)  
Accounts Receivable, Net                        
Write-off and other                 0 0 0  
Advertising                        
Advertising Expense                 513,000 351,000 113,000  
Intangible Assets, Net (Excluding Goodwill) [Abstract]                        
Asset Impairment Charges                 1,571,000      
Sales Revenue, Services, Net [Member] | Exela [Member]
                       
Concentration of Credit Risk                        
Customer concentration risk (percentage)                 15.00% 0.00% 0.00%  
Sales Revenue, Services, Net [Member] | Shell [Member]
                       
Concentration of Credit Risk                        
Customer concentration risk (percentage)                 0.00% 51.00% 51.00%  
Sales Revenue, Services, Net [Member] | Merck [Member]
                       
Concentration of Credit Risk                        
Customer concentration risk (percentage)                 39.00% 13.00% 10.00%  
Sales Revenue, Services, Net [Member] | Novartis [Member]
                       
Concentration of Credit Risk                        
Customer concentration risk (percentage)                 14.00% 1.00% 1.00%  
Prepaid Expenses and Other Current Assets [Member]
                       
Accounting Policies [Line Items]                        
Deferred cost of sales         1,100,000         1,100,000    
Core IP [Member]
                       
Intangible Assets, Net (Excluding Goodwill) [Abstract]                        
Undiscounted cash flows, discount rate (percent)                 19.50% 18.00%    
Undiscounted cash flows, long-term growth rate (percent)                 2.00% 2.00%    
Fair value in excess of carrying value (percent) 44.00%               44.00%      
Percentage of undiscounted cash flows per product (percent) 7.00%       38.00%       7.00% 38.00%    
Percentage of undiscounted cash flows greater than the carrying value of the asset group (percent) 37.00%       14.00%       37.00% 14.00%    
Customer relationships [Member]
                       
Accounting Policies [Line Items]                        
Entity-Wide Revenue, Major Customer, Percentage                 81.00% 83.00%    
Novartis [Member]
                       
Concentration of Credit Risk                        
Customer concentration risk (percentage)                 50.00% 11.00%    
Merck [Member]
                       
Concentration of Credit Risk                        
Customer concentration risk (percentage)                   53.00%    
Arch [Member]
                       
Accounts Receivable, Net                        
Write-off and other                 387,000      
Debt Securities [Member]
                       
Cash, Cash Equivalents and Marketable Securities [Abstract]                        
Recorded impairment in condensed consolidated statement of operations as sales, general and administrative expenses                 0      
Available-for-sale Securities [Member]
                       
Cash, Cash Equivalents and Marketable Securities [Abstract]                        
Realized gains (losses) from sales of marketable securities                 0 0 0  
Impairment of Goodwill [Member]
                       
Intangible Assets, Net (Excluding Goodwill) [Abstract]                        
Asset Impairment Charges                 $ 0 $ 0 $ 0  
Enzyme Opportunities [Member]
                       
Accounting Policies [Line Items]                        
Undiscounted cash flows, expected percentage of revenue (percent)         31.00%         31.00%    
Entity-Wide Revenue, Major Customer, Percentage                 10.00%      
Core Pharmaceutical Business [Member]
                       
Accounting Policies [Line Items]                        
Undiscounted cash flows, expected percentage of revenue (percent)         69.00%         69.00%    
Entity-Wide Revenue, Major Customer, Percentage                 90.00%